Company Opexa Therapeutics Inc Nasdaq
Equities
US68372T2024
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 11-16 |
Tanya Hayden
COO | Chief Operating Officer | 44 | 21-05-31 |
John M. Klopp
CTO | Chief Tech/Sci/R&D Officer | 50 | - |
Jim DeNike
IRC | Investor Relations Contact | - | - |
Bernie Paul
HRO | Human Resources Officer | 65 | 19-04-30 |
Renee Carroll
LAW | General Counsel | - | 19-12-31 |
Jason Kneeland
AUD | Comptroller/Controller/Auditor | - | 17-10-31 |
Kim Tharaldsen
SAM | Sales & Marketing | - | 18-02-04 |
Corporate Officer/Principal | 57 | 13-11-30 | |
Donald Joseph
LAW | General Counsel | 70 | 18-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 11-16 |
Joshua Schafer
BRD | Director/Board Member | 53 | 11-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 24,463,726 | 24,463,726 ( 100.00 %) | 0 | 100.00 % |
Company contact information
![address Opexa Therapeutics Inc](https://cdn.zonebourse.com/static/address/12191752.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+15.82% | 122B | |
+20.35% | 114B | |
+18.05% | 25.71B | |
-25.31% | 19.02B | |
-20.53% | 15.83B | |
-19.67% | 15.32B | |
-46.87% | 14.88B | |
+62.55% | 14.82B | |
+6.34% | 14.1B |